Introduction {#S0001}
============

Gastrointestinal stromal tumours (GIST) or stromal tumours are rare gastrointestinal tract tumours. They represent 0.1--3% of all gastrointestinal neoplasms and can occur at any place within the gastrointestinal tract \[[@CIT0001]--[@CIT0004]\]. Until recently, stromal tumours have been described as a leiomyomas, leiomyosarcomas, or leiomyoblastomas \[[@CIT0005], [@CIT0006]\]. Schaldenbrand and Appelman introduced the term "stromal tumour" in 1984 to define a subset of mesenchymal tumours referred to by several definitions concerning neurogenic or myogenic differentiation \[[@CIT0007]\]. It is widely believed that GIST originate from, or are closely related to, the interstitial cells of Cajal precursors that are responsible for coordinated muscle contraction of the gastrointestinal tract \[[@CIT0001]\]. The tumour is the result of mutations in the genes encoding the KIT membrane receptor (V-Kit Hardy-Zuckerman 4 Feline Sarcoma Viral Oncogene Homolog) or PDGFRA (alpha-type platelet-derived growth factor receptor, platelet-derived growth factor receptor alpha) \[[@CIT0008], [@CIT0009]\]. The consequence of the c-kit proto-oncogene mutation is a membrane receptor protein expression of c-kit (CD117), a tyrosine kinase, which is present in 85--100% of GIST \[[@CIT0010]\]. CD34 antigen is also positive by immunohistochemistry in 60--70% of GIST cases. The absence of this antigen is considered an indicator of non malignancy \[[@CIT0011], [@CIT0012]\]. KIT mutations responsible for the development of stromal tumours occur in exons 9, 11, 13, and 17 and are of a single mutation. Mutation in exon 11 is associated with a better response to imatinib (a selective tyrosine kinase inhibitor) than the mutation in exon 9 \[[@CIT0013]--[@CIT0015]\]. The PDGFRA mutations occur in exons 12, 14, and 18 \[[@CIT0013], [@CIT0014]\]. In 5% of stromal tumours no mutations were observed, suggesting that GIST histogenesis does not always correspond to mutations \[[@CIT0016], [@CIT0017]\].

The GIST tumours can occur in people of any age, but most patients (75%) with GIST are over 50 years old \[[@CIT0018]\]. Stromal tumours are more common in men \[[@CIT0013]\]. Although the vast majority of GISTs are sporadic, rare familial forms have been described \[[@CIT0001], [@CIT0013]\]. Family-observed GIST occur in patients with neurofibromatosis type 1, and in the case of Carney triad, a rare syndrome defined by the simultaneous occurrence of gastric stromal sarcoma, pulmonary chondroma and extra-adrenal paraganglioma \[[@CIT0001], [@CIT0019]\].

The GIST location in the gastrointestinal tract accounts for about 90% of all stromal tumours \[[@CIT0001], [@CIT0011]\]. The most common locations of GIST are the stomach (40--70%), small intestine (20--50%), colon (around 5%), and oesophagus (\< 5%) \[[@CIT0001], [@CIT0013], [@CIT0018]\]. Other less common locations are those outside of the gastrointestinal tract, like mesentery, retroperitoneum, and omentum. However, rare cases have been reported in the gallbladder, pancreas, liver, and urinary bladder. In cases where GIST occurs outside the gastrointestinal tract, the tumours are known as extra-gastrointestinal stromal tumours (EGISTs) \[[@CIT0001]\].

Stachura *et al*. \[[@CIT0010]\] estimate that in Poland there are 400--700 new cases of GIST each year. Symptomatic stromal tumours located in the duodenum are extremely rare. Usually the first symptom is an abnormal resistance in the abdominal cavity detected during palpation \[[@CIT0018], [@CIT0020]\]. In patients with advanced tumours the first symptom can be an acute bleeding from the upper gastrointestinal tract \[[@CIT0018], [@CIT0020]\]. Very often, however, patients report symptoms such as abdominal pain, abdominal distension, fatigue, and anaemia \[[@CIT0021], [@CIT0022]\]. Small asymptomatic lesions in the duodenum may be found incidentally during esophagogastroduodenoscopy, computed tomography, or exploratory laparotomy performed for other indications \[[@CIT0005], [@CIT0018], [@CIT0023]\].

The primary treatment for GIST is a local radical surgery without removal of unchanged lymph nodes, which in the case in tumours; giving no distant metastases remains the "gold standard" \[[@CIT0008], [@CIT0017], [@CIT0024]\]. The GIST tumours, in approximately 35--40% of cases, are characterised by a high risk of recurrence after primary surgery, and approximately 30% of stromal tumours show features of malignancy with evidence of invasion and metastasis formation in the peritoneum and liver \[[@CIT0011]\].

Previous studies have shown that survival depends on the size of the tumour and microscopic characteristics.

Case report {#S0002}
===========

A 63-year-old woman, without previous family history of cancer, was admitted to the Clinical Department of Gastroenterology, 10^th^ Military Clinical Hospital in Bydgoszcz, Poland, for diagnosis of unknown duodenal bulb tumour, identified in an ambulatory esophagogastroduodenoscopy. The patient reported a burning sensation in the oesophagus, regardless of accepted meals, with no improvement after treatment with a proton pump inhibitor. The patient denied abdominal pain, weight loss, fatigue, lack of appetite, tarry stools, or bloody vomiting. Medical history revealed hypertension, hypothyroidism, and bronchial asthma.

The patient was in good condition at the day of admission to the hospital. Her heart rate was 80 bpm, and arterial blood pressure was 160/80 mm Hg. Lung auscultation indicated normal vesicular murmur without evidence of pulmonary obstruction or stagnation. The abdomen was painless in palpation, she had non-enlarged liver and spleen, normal peristalsis, and no perceptible pathological resistance in the abdominal cavity in palpation.

Laboratory tests (blood cell count, ionogram, total bilirubin, glucose, creatinine, transaminases, thyroid hormones, markers CEA, AFP, Ca19.9) performed during hospitalisation gave results without deviations from accepted laboratory standards.

Ambulatory esophagogastroduodenoscopy revealed a polypoid change in the duodenum, 15 mm × 10 mm in diameter, narrowing the light of the intestine. Another esophagogastroduodenoscopy performed during hospitalisation confirmed the presence of a duodenal bulb tumour on the rear wall and the upper curve of the duodenum, 20 mm × 15 mm in diameter, raised to about 10 mm, with a lesion in the top, 6 mm × 8 mm in diameter, filled with inflammatory granulation tissue with visible, translucent, spontaneously bleeding vessels ([Figures 1A](#F0001){ref-type="fig"}--[D](#F0001){ref-type="fig"}).

![Duodenal bulb tumour with lesion in gastroduodenoscopy](PG-9-24233-g001){#F0001}

Tissue samples were taken for histopathological examination, which showed inflammatory granulation tissue. Abdominal computed tomography revealed a solid nodular change in the duodenal bulb, 19 mm × 18 mm × 24 mm in diameter, emanating from the medial wall of the duodenal bulb, and the signal strengthened significantly after intravenous administration of contrast medium ([Figures 2](#F0002){ref-type="fig"} and [3](#F0003){ref-type="fig"}).

![Duodenal bulb tumour (arrows) in computed tomography -- sagittal projection](PG-9-24233-g002){#F0002}

![Duodenal bulb tumour (arrows) in computed tomography -- frontal projection](PG-9-24233-g003){#F0003}

After surgical consultation due to spontaneous bleeding from the tumour, the patient was qualified for elective surgery and submitted to the Department of Surgery, 10^th^ Military Hospital.

Intraoperatively a tumour was found, measuring 20 mm × 20 mm × 30 mm, located around the top bend on the rear-side of the duodenum, penetrating toward the ampulla of Vater. An intraoperative histopathological examination of the tumour was performed. Microscopic examination revealed the presence of malignant cells. Local excision was performed, followed by resection of the duodenum and the upper distal part of the stomach. The duodenal papilla of Vater was closed above. Gastrointestinal continuity was restored by Roux-Y. Regional lymph nodes in the intraoperative study were unchanged. After the procedure, the patient was transferred for 2 days to the Postoperative Intensive Care Unit in the 10^th^ Military Hospital. She was then transferred once more to the Department of Surgery of the 10^th^ Military Hospital. The postoperative course was uneventful. The patient in the eleventh postoperative day was in good condition and was discharged from hospital was referred for further cancer care to the Oncology Centre in Bydgoszcz.

Histopathological examination of a duodenal wall fragment revealed a solid, grey submucosal tumour, 25 mm × 20 mm in diameter.

Macroscopically the examined part of the duodenum was 110 mm length and 50 mm wide, with normal mucosa and a submucosal tumour measuring 25 mm × 20 mm × 30 mm. The surgical cutting line was without neoplastic infiltration. A fragment of body fat was tested, 80 mm × 45 mm in diameter, without neoplastic infiltration. Sections of tissue were stained with haematoxylin and eosin (H + E staining).

The immune-histological chemistry staining of the tumour tissue samples demonstrated a strong expression of CD34 and CD117 and low mitotic index (Ki-67 \< 2%), with a breakdown of figures 6/50 HPF (high power field, a field with high magnification 400×). The tumour identified as GIST. Histopathological staining results are shown in [Figures 4](#F0004){ref-type="fig"}--[6](#F0006){ref-type="fig"}.

![Duodenal GIST histology. H + E staining. Magnification 100×](PG-9-24233-g004){#F0004}

![CD117-positive cells in GIST structure. Immunohistochemical staining. Magnification 200×](PG-9-24233-g005){#F0005}

![The GIST presenting CD-34 expression. Magnification 200×](PG-9-24233-g006){#F0006}

Discussion {#S0003}
==========

Gastrointestinal stromal tumours are the most common tumours of mesenchymal origin occurring within the abdominal cavity. Nonspecific symptoms of GIST and the difficulty of obtaining histological material due to subserous and submucous growth mean that they are usually diagnosed on the basis of the results of postoperative histopathological tissue sample examinations. The final diagnosis of GIST needs to be confirmed with immunostaining and/or molecular detecting mutations in the *Kit* and *PDGFRA* genes. As proposed by the National Institute of Health (NIH), the division of GIST is distinguished by the degree of aggressiveness of tumours: very low, medium, and high aggressiveness. The term "mild" GIST is not in use \[[@CIT0023]\]. This division includes the size of the tumour and the number of mitoses per 50 fields of view at high microscope magnification (400×). The location of the tumour, cellular atypia, tumour cellularity, and the presence of necrosis influence prognosis \[[@CIT0006], [@CIT0011]\]. Tumours with a diameter greater than 10 cm are classified as high-grade tumours, and tumours with high mitotic activity greater than 10/50 of the field of view, regardless of the size of the tumour, have a high degree of tumour aggressiveness \[[@CIT0011]\].

The most effective way of dealing with GIST is surgical resection \[[@CIT0025]\]. Radical surgery gives 42--80% 5-year survival, whereas non-radical surgery gives only 0--8% 5-year survival \[[@CIT0011]\]. In the case of intestinal localisation of GIST, segmental resection of the small intestine or hemicolectomy is performed. The literature states that lymphadenectomy is not justified, because lymph node metastases are rare \[[@CIT0026], [@CIT0027]\]. It is important, however, to avoid damage during the operation of the tumour as it can lead to the intraperitoneal spread of tumour cells \[[@CIT0011], [@CIT0014]\].

Sákra *et al*. state that also a laparoscopic approach appears highly appropriate in most patients, especially in stomach GIST \[[@CIT0028]\]. With small bowel GIST, laparoscopy allows the tumour to be located in order to perform minor laparotomy \[[@CIT0028]\].

A large percentage of patients are those with incidental GIST. Incidentally detected gastrointestinal stromal tumours are usually small in size and are not visible in imaging studies. Gastroduodenoesophagoscopy, endoscopic ultrasound, and computed tomography with oral and intravenous contrast are most commonly used in the diagnosis of gastrointestinal stromal tumours. Due to the subserous and submucous location of stromal tumours, usually no adequate tissue samples are taken with standard biopsy forceps. In our case, GIST was confirmed with postoperative histopathological material.

In the treatment of inoperable or metastatic GIST, targeted therapy with imatinib, which is a selective inhibitor of tyrosine kinases, is applied. In case of intolerance or resistance to imatinib treatment, sunitinib is the drug of choice \[[@CIT0003], [@CIT0009]\].

The recurrence rate of GIST is 40--80%. Frequently relapse involves a local growth or liver metastases \[[@CIT0011], [@CIT0029]\]. It is believed that even after radical surgical treatment, imatinib should be used \[[@CIT0011]\].

Conclusions {#S0004}
===========

Stromal tumours are a heterogeneous group of mesenchymal neoplasms, with an unpredictable clinical course. Because of the heterogeneous cell structure, histological structure, and mitotic activity of polymorphic angiogenesis, it is important to analyse the numerous segments of the tumour at the border of the surgical cutting. The "Gold standard" in the diagnosis of GIST are immunohistochemical studies using a panel of antibodies: CD117, CD34, dog1, vimentin (mesenchymal cell marker), SMA (smooth muscle actin), desmin (a marker of muscle cells), proteins S100, and HMB45 \[[@CIT0014]\].

Treatment for initial operational changes is radical surgery, and in the case of advanced disease process pharmacotherapy is used. In Poland imatinib is registered as the drug of choice.

Due to the risk of relapse, patients should be supervised. Such patients should have an abdominal CT scan performed every 3--4 months for the first 2 years after surgery, then every 6 months up to 5 years after surgery, and every year after 5 years of treatment \[[@CIT0014]\]. In the case of GIST with a low risk of recurrence, tests should be performed once a year \[[@CIT0014]\].

Gathering more information on the treatment of GIST and its results will enable the development of more precise rules for the assessment of stage and grade. We are still waiting for the results of phase II and III clinical trials on new drugs such as nilotinib, motesanib, everolimus, dasatinib, and sorafenib \[[@CIT0003], [@CIT0009]\].
